Pfizer Animal Health
Equine Rhinopneumonitis Vaccine, Modified Live Virus
U.S. Vet. Lic. No.: 189
Description: RHINOMUNE® is prepared by growing an attenuated strain of EHV-1
on an equine cell line and is packaged in freeze-dried form. The sterile diluent
is used to rehydrate the freeze-dried component.
Contains gentamicin as preservative.
Indications: RHINOMUNE® is for vaccination of healthy horses 3 months of age
or older as an aid in preventing respiratory disease caused by equine
herpesvirus type 1 (EHV-1).
1. General Directions: Vaccination of all horses on the premises
is recommended to enhance herd immunity. Aseptically rehydrate the freeze-dried
vaccine with the sterile diluent provided, shake well, and administer 1 mL
intramuscularly. Appropriate preparation of the inoculation site is advised to
prevent introduction of bacterial contaminants.
2. Primary Vaccination: Healthy horses 3 months of age or older
should receive 2 doses administered 3-4 weeks apart. Foals should be vaccinated
when maternal antibodies have declined, generally at 3 months of age. If
vaccinated earlier, foals should receive the 2-dose series after reaching 3
months of age. Pregnant mares should be vaccinated after the second month of
3. Revaccination: Revaccination every 3 months with a single dose
4. Good animal husbandry and herd health management practices
should be employed.
Precaution(s): Store at 2°-7°C. Prolonged
exposure to higher temperatures and/or direct sunlight may adversely affect
potency. Do not freeze.
Use entire contents when first opened.
Sterilized syringes and needles should be used to administer this
vaccine. Do not sterilize with chemicals because traces of disinfectant may
inactivate the vaccine.
Burn containers and all unused contents.
Caution(s): As with many vaccines, anaphylaxis
may occur after use. Initial antidote of epinephrine is recommended and should
be followed with appropriate supportive therapy.
This product has been shown to be efficacious in healthy animals.
A protective immune response may not be elicited if animals are incubating an
infectious disease, are malnourished or parasitized, are stressed due to
shipment or environmental conditions, are otherwise immunocompromised, or the
vaccine is not administered in accordance with label directions.
Warning(s): Do not vaccinate within 21 days
For veterinary use only.
Discussion: Disease Description: Primary
infection with EHV-1 causes an acute respiratory disease characterized by nasal
discharge, coughing, labored breathing, fever, slight loss of appetite, and
depression. Annual outbreaks may occur among foals in areas with a large equine
population. Clinical signs, occasionally persisting as long as 7 days, are
generally more severe in young horses, and may be exacerbated by strenuous
activity. Subclinical reinfection may also occur, with latent carriers the
probable reservoir of EHV-1. Immunity following natural infection typically
endures for 3-9 months and is usually enhanced by subclinical or mild
Trial Data: Safety and Efficacy: In extensive
laboratory and field tests, no adverse reactions were reported in vaccinated
horses, including young, susceptible foals and pregnant mares. Mares vaccinated
after the second month of pregnancy remained clinically normal and delivered
live, healthy foals. In challenge-of-immunity tests, vaccinated horses remained
clinically normal after challenge with EHV-1 that produced typical signs of
respiratory disease in nonvaccinated horses.
References: Available upon request.
Presentation: 1 dose and 5 dose vials.
NAC No.: 36901360